Document is current
Any future updates will be listed below
-
Authors
Kim, Jiyoen
Tadros, Bakhos
Liang, Yan Hong
Kim, Youngdoo https://orcid.org/0000-0003-3231-7371
Lasagna-Reeves, Cristian https://orcid.org/0000-0002-5499-3082
Sonn, Jun Young
Chung, Dah-eun Chloe
Hyman, Bradley https://orcid.org/0000-0002-7959-9401
Holtzman, David M. https://orcid.org/0000-0002-3400-0856
Zoghbi, Huda Yahya https://orcid.org/0000-0002-0700-3349
-
Funding
Funding for this research was provided by:
JPB Foundation (N/A, N/A)
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1R01NS119280)
- License Information
-
More Information
Article History
Received: 21 August 2023
Accepted: 28 August 2024
First Online: 11 November 2024
Competing interests
: H.Y.Z. cofounded Cajal Neuroscience, is a director of the Regeneron Pharmaceuticals board and is on the scientific advisory board of Cajal Neuroscience, Lyterian and the Column Group. D.M.H. cofounded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Cajal Neuroscience and Genentech, consults for Asteroid Therapeutics, is an inventor of and has a patent on antitau antibodies that was licensed by Washington University to C2N Diagnostics. B.H. owns stock in Novartis; he serves on the scientific advisory board of Dewpoint and has an option for stock. He serves on a scientific advisory board or is a consultant for AbbVie, Alexion, Ambagon, Aprinoia Therapeutics, Arvinas, Avrobio, AstraZeneca, Biogen, BMS, Cure Alz Fund, Cell Signaling Technology, Dewpoint, Latus, Novartis, Pfizer, Sanofi, Sofinnova, Vigil, Violet, Voyager and WaveBreak. His laboratory is supported by research grants from the NIH, Cure Alzheimer’s Fund, Tau Consortium and the JPB Foundation, as well as a sponsored research agreement from Abbvie. The other authors declare no competing interests.
